Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOPEC: Nivolumab and dendritic cell therapy with CRS-HIPEC in peritoneal mesothelioma
2024-519626-21-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and MesoPher in peritoneal mesothelioma, sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Planned start Apr 2025; status: authorised.
02
Drugs
nivolumabMesoPher
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on 2024-519626-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519626-21-00.